🚨 $GSK announces its 2024 earnings results, showcasing a sales increase of 8% to over £31 billion, driven by specialty medicines and significant profit growth📈. Core operating profit rose by 13%, with core EPS up 12%. However, vaccine sales faced challenges, impacting short-term growth forecasts. 💉 The outlook for 2025 anticipates continued robust growth, particularly in specialty medicines, with five new product approvals expected. 📊 For more details, visit valueverge.com/GSK.
